September 27, 2016 10:31 AM ET

Biotechnology

Company Overview of Boston Biomedical, Inc.

Company Overview

Boston Biomedical, Inc. focuses on the research and development of cancer therapeutics. Its product pipeline comprises BBI608 is an orally-administered investigational agent designed to inhibit cancer stem cell pathways by targeting STAT3; and BBI503, an orally-administered investigational agent designed to inhibit Nanog and other cancer stem cell pathways by targeting kinases. The company was founded in 2006 and is based in Cambridge, Massachusetts. As of April 24, 2012, Boston Biomedical, Inc. operates as a subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

640 Memorial Drive

Cambridge, MA 02139

United States

Founded in 2006

Phone:

617-674-6800

Fax:

617-674-8661

Key Executives for Boston Biomedical, Inc.

Founder, Chief Executive Officer, President and Chief Medical Officer
Age: 51
Chief Commercial Officer and Executive Vice President
Age: 57
Vice President of Product Development & Business Affairs
Compensation as of Fiscal Year 2016.

Boston Biomedical, Inc. Key Developments

Boston Biomedical Announces Clinical Data on the Investigational Compounds BBI608 and BBI503

Boston Biomedical announced that it will present clinical data on the investigational compounds BBI608 and BBI503 in multiple tumor types at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Data presented at ASCO highlight the potential of BBI608 -- an orally-administered investigational agent that targets STAT3, leading to inhibition of the critical genes for maintaining cancer stemness -- for anti-cancer activity when used in combination with other chemotherapeutics across varying advanced cancers, including gastric and colorectal. Additionally, as part of the "trials in progress" program, the study protocol from the BRIGHTER study, a phase 3 clinical trial currently underway to investigate cancer stem cell pathway inhibition, is also showcased. Additional data featuring BBI503 -- an orally-administered investigational agent designed to inhibit Nanog and other cancer stem cell pathways by targeting kinases -- showed encouraging early signs of anti-cancer activity for patients with advanced colorectal cancer. Boston Biomedical poster presentations include: Abstract #4069, Poster #179: BBI608-201: Phase 1b/2 study of cancer stemness inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Data from the study showed BBI608 and weekly paclitaxel can be combined in patients with advanced pre-treated gastric/GEJ cancer. Lesion regression, objective responses, and prolonged stable disease were observed in heavily pre-treated patients. In evaluable patients who had not previously received a taxane in the metastatic setting, and who received one prior line of therapy (n=6), namely the patients that meet the enrollment criteria for the BRIGHTER trial, an objective response rate (ORR) of 50% was observed. In heavily pretreated patients (failed average >2 lines of prior therapies) who had not previously received a taxane in the metastatic setting (n=16), the ORR was 31% in the per-protocol population. The disease control rate (DCR) was 75%; median progression-free survival (mPFS) was 20.6 weeks and median overall survival (mOS) was 39.3 weeks. Most common adverse events were grade 1 to 2 diarrhea, nausea, vomiting and abdominal pain. Grade 3 adverse events included vomiting (8.7%), diarrhea of 5 days or longer (6.5%), fatigue (6.5%), abdominal and gastrointestinal pain, nausea, dehydration, anorexia, white blood cell decrease and acute kidney injury (2.2% each). Continued evaluation of this combination and patient population, specifically in those patients who received one prior line of therapy, is currently underway in the phase 3 BRIGHTER study. Abstract #TPS4139, Poster #247a: The BRIGHTER trial: A phase 3 randomized, double-blind, placebo-controlled clinical trial of first-in-class cancer stemness inhibitor BBI608 plus weekly paclitaxel versus placebo plus weekly paclitaxel in adult patients with advanced, previously treated gastric and gastro-esophageal junction (GEJ) adenocarcinoma. The goal of the BRIGHTER trial (NCT02178956) is to determine if BBI608 given together with paclitaxel as second-line therapy will extend survival compared to treatment with paclitaxel alone. Enrollment is ongoing at multiple sites in North America, Europe, Australia and Japan. BBI608 blocks cancer stem cell renewal and survival by suppressing stemness pathways, including STAT3, beta-catenin and immune checkpoint gene expression. Abstract #3616, Poster #109: BBI608-246: A phase 1b study of first-in-class cancer stemness inhibitor BBI608 in combination with FOLFIRI with and without Bevacizumab in patients with advanced colorectal cancer. Data from the study showed that BBI608 at 240 mg BID can be combined with FOLFIRI, with or withoutbevacizumab, in patients with advanced and heavily pretreated colorectal cancer (CRC). Disease control, measured by partial response and stable disease, was observed in 100% of evaluable patients (n=9), including 6 patients who had failed FOLFIRI previously, with partial response in 2/9 patients and stable disease in 7/9 patients, all of whom (9/9 patients) experienced signs of tumor regression. Prolonged stable disease (more than or equal to 6 months) was observed in 5/9 patients (55.6%) of evaluable patients. The median progression-free survival was 23.7 weeks. Abstract #3617, Poster #110: BBI608-224: A phase 1b/2 study of cancer stemness inhibitor BBI608 administered with Panitumumab in KRAS wild-type patients with metastatic colorectal cancer. Results from the study found that BBI608 and bi-weekly panitumumab can be combined at the full dose of 480-500 mg BID. Abstract #3615, Poster #108: BBI503-101: Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer. The findings indicated that BBI503 as a monotherapy was tolerated at the recommended phase 2 dose of 300 mg once daily.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Boston Biomedical, Inc., please visit www.bostonbiomedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.